- Home
- RCKT vs RIGL Comparison
RCKT vs RIGL Comparison
Compare RCKT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- RIGL
- Stock Information
- Founded
- RCKT 1999
- RIGL 1996
- Country
- RCKT United States
- RIGL United States
- Employees
- RCKT N/A
- RIGL N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- RIGL Health Care
- Exchange
- RCKT Nasdaq
- RIGL Nasdaq
- Market Cap
- RCKT 328.6M
- RIGL 335.5M
- IPO Year
- RCKT N/A
- RIGL 2000
- Fundamental
- Price
- RCKT $3.28
- RIGL $38.85
- Analyst Decision
- RCKT Buy
- RIGL Buy
- Analyst Count
- RCKT 13
- RIGL 5
- Target Price
- RCKT $12.96
- RIGL $38.20
- AVG Volume (30 Days)
- RCKT 6.0M
- RIGL 995.6K
- Earning Date
- RCKT 08-07-2025
- RIGL 08-05-2025
- Dividend Yield
- RCKT N/A
- RIGL N/A
- EPS Growth
- RCKT N/A
- RIGL N/A
- EPS
- RCKT N/A
- RIGL 5.43
- Revenue
- RCKT N/A
- RIGL $267,921,000.00
- Revenue This Year
- RCKT N/A
- RIGL $59.93
- Revenue Next Year
- RCKT $108.43
- RIGL N/A
- P/E Ratio
- RCKT N/A
- RIGL $7.15
- Revenue Growth
- RCKT N/A
- RIGL 105.62
- 52 Week Low
- RCKT $2.19
- RIGL $12.66
- 52 Week High
- RCKT $22.01
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- RCKT 51.17
- RIGL 68.57
- Support Level
- RCKT $2.88
- RIGL $39.00
- Resistance Level
- RCKT $3.74
- RIGL $42.08
- Average True Range (ATR)
- RCKT 0.27
- RIGL 2.32
- MACD
- RCKT 0.02
- RIGL -0.37
- Stochastic Oscillator
- RCKT 35.43
- RIGL 53.26
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.